RxSight Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
On August 30, 2024, Robert Warner, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) for the sale of securities of our common stock. Mr. Warner's Rule 10b5-1 Trading Plan, which has a term from August 30, 2024 to August 29, 2025, provides for the sale of up to 12,817 shares of common stock at a pre-determined limit prices.
On August 22, 2024, Shweta Maniar, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”) for the sale of securities of our common stock. Ms. Maniar’s Rule 10b5-1 Trading Plan, which has a term from November 26, 2024 to November 26, 2025, provides for the sale of up to 12,130 shares of common stock at a pre-determined limit prices.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.